Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Cytokinetics to present at major June healthcare investor conferences

CYTK

$74.19

-$2.57 -3.34%

Cytokinetics to present at major June healthcare investor conferences

Name: Pluang-Trading US Stock Crypto
Availability: InStock
Rating: 4.75 (118984 reviews)
Author: pluang

Market News

27 May 2026

GlobeNewsWire

View Source

Neutral

Cytokinetics announced that its management team will participate in two key investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8. These events will include fireside chats accessible via live webcast on the company's website. Cytokinetics is advancing its cardiovascular drug pipeline, including the approved MYQORZO for obstructive hypertrophic cardiomyopathy and investigational drugs like omecamtiv mecarbil and ulacamten. The company plans to present full Phase 3 trial results for aficamten soon and engage with regulatory authorities, highlighting its ongoing development efforts in cardiac muscle disease treatments.

More News (CYTK)

MYQORZO® (aficamten) launches in Germany to treat obstructive hypertrophic cardiomyopathy, following EU approval.

Cytokinetics has launched MYQORZO® (aficamten) in Germany for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults, following its approval by the European Commission in February 2026. The drug, which inhibits cardiac myosin t...

Company Fundamentals

Bullish

8 hours ago